Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2022-10-26 | Reverse | 1:20 |
Talphera, Inc. is a California-based specialty pharmaceutical company developing therapies like Niyad, LTX-608, Fedsyra, and PFS-02 for medically supervised settings, focusing on anticoagulation, anti-inflammation, and viral conditions.

Niyad is a lyophilized nafamostat anticoagulant for extracorporeal circuits, FDA Breakthrough Designated, and Talphera's lead product, marking its shift toward innovative therapies for patients intolerant to heparin.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
NTRB | $5.77 | COMPARE |
SCYX | $5.28 | COMPARE |
MIRA | $0.76 | COMPARE |
PIII | $9.00 | COMPARE |
IBIO | $1.29 | COMPARE |
COSM | $0.26 | COMPARE |
INTS | $4.06 | COMPARE |